CTC and Recipharm, leading Contract Development and Manufacturing Organisation (CDMO) company in the pharmaceutical industry, have strengthened their cooperation through the divestment of Recipharm's GLP laboratory to the Center for Translational Research AB (CTR).
CTR is the Uppsala-based parent company of CTC Clinical Trial Consultants. Recipharm and CTC Clinical Trial Consultants began a collaboration in 2017 by forming the Recipharm Pathway to Clinic. An integrated service that offers a clear, optimized path to first-in human. As part of the solution, Recipharm performs formulation development and GMP the manufacture of clinical substances, while CTC Clinical Trial Consultants is responsible for clinical studies in the early stages (phase 0 – IIa).
The GLP laboratory will continue its operations as a newly formed company under the name Lablytica Life Science AB, as one of the CTR wholly owned company. Analysis activities continue without interruption with the same staff, facilities, instrumentation and most importantly, with the same validated analytical methods. David Pekar will continue to lead the team as Chief Scientific Officer.